-
Je něco špatně v tomto záznamu ?
Extending the viability of human precision-cut intestinal slice model for drug metabolism studies
C. Biel, O. Martinec, B. Sibering, K. van Summeren, AMA. Wessels, DJ. Touw, KP. de Jong, VE. de Meijer, KN. Faber, JPT. Klooster, IAM. de Graaf, P. Olinga
Jazyk angličtina Země Německo
Typ dokumentu časopisecké články
NLK
ProQuest Central
od 2002-01-01 do Před 1 rokem
Medline Complete (EBSCOhost)
od 2000-01-01 do Před 1 rokem
Health & Medicine (ProQuest)
od 2002-01-01 do Před 1 rokem
Public Health Database (ProQuest)
od 2002-01-01 do Před 1 rokem
- MeSH
- kultivační média MeSH
- lidé MeSH
- metabolická inaktivace MeSH
- midazolam * farmakologie MeSH
- organoidy MeSH
- střeva * MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
Human Precision-cut intestinal slices (hPCIS) are used to study intestinal physiology, pathophysiology, drug efficacy, toxicology, kinetics, and metabolism. However, the use of this ex vivo model is restricted to approximately a 24 h timeframe because of declining viability of the hPCIS during traditional culture. We hypothesized that we could extend the hPCIS viability by using organoid medium. Therefore, we cultured hPCIS for up to 72 h in organoid media [expansion medium (Emed) and differentiation medium (Dmed)]. After incubation, we assessed culture-induced changes on viability markers, specific cell type markers and we assessed the metabolic activity of enterocytes by measuring midazolam metabolite formation. We show that the adenosine triphosphate (ATP)/protein ratio of Emed-cultured hPCIS and morphology of both Emed- and Dmed-cultured hPCIS was improved compared to WME-cultured hPCIS. Emed-cultured hPCIS showed an increased expression of proliferation and stem cell markers, whereas Dmed-cultured hPCIS showed an increased expression of proliferation and enterocyte markers, along with increased midazolam metabolism. Using the Emed, the viability of hPCIS could be extended for up to 72 h, and proliferating stem cells remained preserved. Using Dmed, hPCS also remained viable for up to 72 h, and specifically rescued the metabolizing enterocytes during culture. In conclusion, by using two different organoid culture media, we could extend the hPCIS viability for up to 72 h of incubation and specifically steer stem cells or enterocytes towards their original function, metabolism, and proliferation, potentially allowing pharmacokinetic and toxicology studies beyond the 24 h timeframe.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22018097
- 003
- CZ-PrNML
- 005
- 20220804134543.0
- 007
- ta
- 008
- 220720s2022 gw f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s00204-022-03295-1 $2 doi
- 035 __
- $a (PubMed)35428896
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Biel, C $u Department of Pharmaceutical Technology and Biopharmacy, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, The Netherlands
- 245 10
- $a Extending the viability of human precision-cut intestinal slice model for drug metabolism studies / $c C. Biel, O. Martinec, B. Sibering, K. van Summeren, AMA. Wessels, DJ. Touw, KP. de Jong, VE. de Meijer, KN. Faber, JPT. Klooster, IAM. de Graaf, P. Olinga
- 520 9_
- $a Human Precision-cut intestinal slices (hPCIS) are used to study intestinal physiology, pathophysiology, drug efficacy, toxicology, kinetics, and metabolism. However, the use of this ex vivo model is restricted to approximately a 24 h timeframe because of declining viability of the hPCIS during traditional culture. We hypothesized that we could extend the hPCIS viability by using organoid medium. Therefore, we cultured hPCIS for up to 72 h in organoid media [expansion medium (Emed) and differentiation medium (Dmed)]. After incubation, we assessed culture-induced changes on viability markers, specific cell type markers and we assessed the metabolic activity of enterocytes by measuring midazolam metabolite formation. We show that the adenosine triphosphate (ATP)/protein ratio of Emed-cultured hPCIS and morphology of both Emed- and Dmed-cultured hPCIS was improved compared to WME-cultured hPCIS. Emed-cultured hPCIS showed an increased expression of proliferation and stem cell markers, whereas Dmed-cultured hPCIS showed an increased expression of proliferation and enterocyte markers, along with increased midazolam metabolism. Using the Emed, the viability of hPCIS could be extended for up to 72 h, and proliferating stem cells remained preserved. Using Dmed, hPCS also remained viable for up to 72 h, and specifically rescued the metabolizing enterocytes during culture. In conclusion, by using two different organoid culture media, we could extend the hPCIS viability for up to 72 h of incubation and specifically steer stem cells or enterocytes towards their original function, metabolism, and proliferation, potentially allowing pharmacokinetic and toxicology studies beyond the 24 h timeframe.
- 650 _2
- $a kultivační média $7 D003470
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a metabolická inaktivace $7 D008658
- 650 12
- $a střeva $7 D007422
- 650 12
- $a midazolam $x farmakologie $7 D008874
- 650 _2
- $a organoidy $7 D009940
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Martinec, O $u Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Kralove, Charles University, Prague, Czech Republic $u Department of Medical Biochemistry, Faculty of Medicine in Hradec Kralove, Charles University, Prague, Czech Republic
- 700 1_
- $a Sibering, B $u Department of Pharmaceutical Technology and Biopharmacy, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, The Netherlands
- 700 1_
- $a van Summeren, K $u Innovative Testing in Life Science & Chemistry Group, Utrecht University of Applied Science, Utrecht, The Netherlands
- 700 1_
- $a Wessels, A M A $u Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, Groningen, The Netherlands
- 700 1_
- $a Touw, D J $u Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, Groningen, The Netherlands $u Department of Pharmaceutical Analysis, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, The Netherlands
- 700 1_
- $a de Jong, K P $u Department of Hepato-Pancreato-Biliary Surgery and Liver Transplantation, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands
- 700 1_
- $a de Meijer, V E $u Department of Hepato-Pancreato-Biliary Surgery and Liver Transplantation, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands
- 700 1_
- $a Faber, K N $u Department of Gastroenterology and Hepatology, University Medical Centre Groningen, Groningen, The Netherlands
- 700 1_
- $a Klooster, J P Ten $u Innovative Testing in Life Science & Chemistry Group, Utrecht University of Applied Science, Utrecht, The Netherlands
- 700 1_
- $a de Graaf, I A M $u Department of Pharmacokinetics, Toxicology & Targeting, Groningen Research Institute of Pharmacy University of Groningen, Groningen, The Netherlands
- 700 1_
- $a Olinga, P $u Department of Pharmaceutical Technology and Biopharmacy, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, The Netherlands. p.olinga@rug.nl $1 https://orcid.org/0000000348558452
- 773 0_
- $w MED00009265 $t Archives of toxicology $x 1432-0738 $g Roč. 96, č. 6 (2022), s. 1815-1827
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/35428896 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220720 $b ABA008
- 991 __
- $a 20220804134537 $b ABA008
- 999 __
- $a ok $b bmc $g 1821929 $s 1169340
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 96 $c 6 $d 1815-1827 $e 20220415 $i 1432-0738 $m Archives of toxicology $n Arch Toxicol $x MED00009265
- LZP __
- $a Pubmed-20220720
